Literature DB >> 33763795

Meibomian gland dysfunction in geriatric population: tehran geriatric eye study.

Hassan Hashemi1, Amir Asharlous2, Mohamadreza Aghamirsalim3, Abbasali Yekta4, Rama Pourmatin5, Masoome Sajjadi5, Mojgan Pakbin1, Mohammadreza Asadollahi1, Mehdi Khabazkhoob6.   

Abstract

PURPOSE: To determine the prevalence of Meibomian gland dysfunction (MGD) and its risk factors in an elderly Iranian population
METHODS: This cross-sectional study was conducted in 2019. The target population was the subjects aged 60 and over living in Tehran. Multistage cluster sampling was done to select the subjects from all Tehran districts. After an initial interview, all subjects underwent complete ophthalmic examinations including the measurement of visual acuity and refraction as well as slit lamp biomicroscopy to evaluate Meibomian glands.
RESULTS: Of 3791 selected subjects, 3310 participated in the study. The data of 3284 participants were analyzed. The mean age of the subjects was 68.24 ± 6.53 years (range: 60-97 years) and 57.8% of them were female. The total prevalence of MGD was 71.2% (68.3-74.1), and 38.1% (8.35-40.4), 30.3% (27.4-33.2), and 2.8% (2-3.6) of the subjects had MGD stage 2, 3, and 4, respectively. The prevalence of MGD was significantly higher in men (p < 0.001) and increased with age from 64.4% in the age group 60-64 years to 82.4% in subjects aged 80 years and over. There was no significant difference in the prevalence of MGD between smokers and nonsmokers; however, severe MGD was more common in smokers. The prevalence of MGD was 76.3% and 68.52% in subjects with and without a history of ocular surgery, respectively. The prevalence of MGD stage 3 and 4 was higher in subjects with a history of ocular surgery.
CONCLUSIONS: In line with the results of other studies in Asian countries, this study found a high prevalence of MGD in an elderly population of Iran. It was found that male gender and advanced age were risk factors of MGD and smoking and history of ocular surgery might worsen this disease in MGD patients.

Entities:  

Keywords:  Eyelid; Meibomian glands; Prevalence; Risk factor

Year:  2021        PMID: 33763795     DOI: 10.1007/s10792-021-01812-2

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  39 in total

1.  Molecular structure of interfacial human meibum films.

Authors:  Danielle L Leiske; Chad E Miller; Liat Rosenfeld; Colin Cerretani; Alexander Ayzner; Binhua Lin; Mati Meron; Michelle Senchyna; Howard A Ketelson; David Meadows; Sruthi Srinivasan; Lyndon Jones; Clayton J Radke; Michael F Toney; Gerald G Fuller
Journal:  Langmuir       Date:  2012-08-01       Impact factor: 3.882

Review 2.  Impact of dry eye disease and treatment on quality of life.

Authors:  Neil J Friedman
Journal:  Curr Opin Ophthalmol       Date:  2010-07       Impact factor: 3.761

Review 3.  The international workshop on meibomian gland dysfunction: executive summary.

Authors:  Kelly K Nichols; Gary N Foulks; Anthony J Bron; Ben J Glasgow; Murat Dogru; Kazuo Tsubota; Michael A Lemp; David A Sullivan
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

Review 4.  TFOS DEWS II Epidemiology Report.

Authors:  Fiona Stapleton; Monica Alves; Vatinee Y Bunya; Isabelle Jalbert; Kaevalin Lekhanont; Florence Malet; Kyung-Sun Na; Debra Schaumberg; Miki Uchino; Jelle Vehof; Eloy Viso; Susan Vitale; Lyndon Jones
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

5.  Dry eye disease, dry eye symptoms and depression: the Beijing Eye Study.

Authors:  Antoine Labbé; Ya Xing Wang; Ying Jie; Christophe Baudouin; Jost B Jonas; Liang Xu
Journal:  Br J Ophthalmol       Date:  2013-09-07       Impact factor: 4.638

6.  Prevalence and risk factors of meibomian gland dysfunction: the Singapore Malay eye study.

Authors:  Jay J K Siak; Louis Tong; Wan Ling Wong; Howard Cajucom-Uy; Mohamad Rosman; Seang Mei Saw; Tien Yin Wong
Journal:  Cornea       Date:  2012-11       Impact factor: 2.651

7.  The association of meibomian gland dysfunction and other common ocular diseases with dry eye: a population-based study in Spain.

Authors:  Eloy Viso; Francisco Gude; María Teresa Rodríguez-Ares
Journal:  Cornea       Date:  2011-01       Impact factor: 2.651

8.  The features of dry eye disease in a Japanese elderly population.

Authors:  Miki Uchino; Murat Dogru; Yukiko Yagi; Eiki Goto; Masao Tomita; Takashi Kon; Megumi Saiki; Yukihiro Matsumoto; Yuichi Uchino; Norihiko Yokoi; Shigeru Kinoshita; Kazuo Tsubota
Journal:  Optom Vis Sci       Date:  2006-11       Impact factor: 1.973

Review 9.  A Review on Evidence-Based Treatments for Meibomian Gland Dysfunction.

Authors:  Pun Yuet Lam; Kendrick Co Shih; Pak Yui Fong; Tommy Chung Yan Chan; Alex Lap-Ki Ng; Vishal Jhanji; Louis Tong
Journal:  Eye Contact Lens       Date:  2020-01       Impact factor: 2.018

10.  Benefits of omega-3 fatty acid dietary supplementation on health-related quality of life in patients with meibomian gland dysfunction.

Authors:  Andrea Oleñik; Ignacio Mahillo-Fernández; Nicolás Alejandre-Alba; Guillermo Fernández-Sanz; María Alarcón Pérez; Sol Luxan; Silvia Quintana; Alfonso Martínez de Carneros Llorente; Blanca García-Sandoval; Ignacio Jiménez-Alfaro
Journal:  Clin Ophthalmol       Date:  2014-04-30
View more
  1 in total

1.  Meibomian Gland Morphology Changes After Cataract Surgery: A Contra-Lateral Eye Study.

Authors:  Pingjun Chang; Shuyi Qian; Zhizi Xu; Feng Huang; Yinying Zhao; Zhangliang Li; Yun-E Zhao
Journal:  Front Med (Lausanne)       Date:  2021-11-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.